AstraZeneca: Covid-19 antibody advances, gets US funding
(CercleFinance.com) - AstraZeneca said that its long-acting antibody combination for the prevention of Covid-19 will advance into two phase-III clinical trials.
More than 6,000 participants are due to begin trials in the next weeks, the drugmaker said on Monday.
The antibodies - which have been engineered with AstraZeneca's proprietary technology - have been designed to increase the durability of the therapy for 6 to 12 months following a single administration.
The combination is also made to reduce the risk of resistance developed by the coronavirus.
In its statement, AstraZeneca said that it has received support of around 486 million dollars from the US Government for the development and supply of the drug.
Under this deal, the biopharmaceutical company plans to supply up to 100,000 doses starting towards the end of 2020, with the US Government having an option to buy up to an additional one million doses in 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
More than 6,000 participants are due to begin trials in the next weeks, the drugmaker said on Monday.
The antibodies - which have been engineered with AstraZeneca's proprietary technology - have been designed to increase the durability of the therapy for 6 to 12 months following a single administration.
The combination is also made to reduce the risk of resistance developed by the coronavirus.
In its statement, AstraZeneca said that it has received support of around 486 million dollars from the US Government for the development and supply of the drug.
Under this deal, the biopharmaceutical company plans to supply up to 100,000 doses starting towards the end of 2020, with the US Government having an option to buy up to an additional one million doses in 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.